(VIANEWS) – Penske Automotive Group (PAG), Proto Labs (PRLB), Catalyst Pharmaceuticals (CPRX) are the highest sales growth and return on equity stocks on this list.

Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?

1. Penske Automotive Group (PAG)

20.8% sales growth and 29.73% return on equity

Penske Automotive Group, Inc., a diversified transportation services company, operates automotive and commercial truck dealerships.

Penske Automotive Group’s sales growth this year is anticipated to be 20.6% and 5.8% for next year.

Year-on-year quarterly revenue growth grew by 91.4%, now sitting on 24.54B for the twelve trailing months.

Volume

Today’s last reported volume for Penske Automotive Group is 463574 which is 65.17% above its average volume of 280672.

Penske Automotive Group’s sales growth for the next quarter is 20.8%. The company’s growth estimates for the current quarter and the next is 278.6% and negative -21.5%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 29.73%.

Volatility

Penske Automotive Group’s last day, last week, and last month’s current volatility was 7.43%, 1.98%, and 1.95%, respectively.

Penske Automotive Group’s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 7.12% (day), 3.59% (last week), and 3.28% (last month), respectively.

Penske Automotive Group’s Stock Yearly Top and Bottom Value

Penske Automotive Group’s stock is valued at $87.09 at 01:22 EST, under its 52-week high of $93.45 and way above its 52-week low of $44.39.

Penske Automotive Group’s Moving Average

Penske Automotive Group’s worth is way higher than its 50-day moving average of $77.57 and way above its 200-day moving average of $77.80.

2. Proto Labs (PRLB)

16.8% sales growth and 5.79% return on equity

Proto Labs, Inc., together with its subsidiaries, operates as an e-commerce driven digital manufacturer of custom prototypes and on-demand production parts in the worldwide.

Proto Labs’s sales growth this year is expected to be 12.4% and 9.1% for next year.

Year-on-year quarterly revenue growth grew by 0.9%, now sitting on 435.41M for the twelve trailing months.

Volume

Today’s last reported volume for Proto Labs is 609948 which is 50.24% above its average volume of 405985.

Proto Labs’s sales growth for the next quarter is 16.8%. The company’s growth estimates for the current quarter and the next is a negative 25.4% and negative -25.4%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.79%.

Volatility

Proto Labs’s last day, last week, and last month’s current volatility was 8.33%, 2.44%, and 2.29%, respectively.

Proto Labs’s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 10.46% (day), 4.80% (last week), and 3.92% (last month), respectively.

Proto Labs’s Stock Yearly Top and Bottom Value

Proto Labs’s stock is valued at $77.77 at 01:22 EST, way below its 52-week high of $286.57 and higher than its 52-week low of $77.71.

Proto Labs’s Moving Average

Proto Labs’s value is way under its 50-day moving average of $88.54 and way below its 200-day moving average of $124.48.

3. Catalyst Pharmaceuticals (CPRX)

15.8% sales growth and 51.9% return on equity

Catalyst Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States.

Catalyst Pharmaceuticals’s sales growth this year is expected to be 10.2% and 14.4% for next year.

Year-on-year quarterly revenue growth grew by 3.7%, now sitting on 120.14M for the twelve trailing months.

Volume

Today’s last reported volume for Catalyst Pharmaceuticals is 479636 which is 60.02% below its average volume of 1199760.

Catalyst Pharmaceuticals’s sales growth is a negative 0% for the ongoing quarter and 15.8% for the next. The company’s growth estimates for the present quarter and the next is a negative 0% and negative -73.2%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 51.9%.

Volatility

Catalyst Pharmaceuticals’s last day, last week, and last month’s current volatility was 1.03%, 1.67%, and 1.61%, respectively.

Catalyst Pharmaceuticals’s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 3.95% (day), 4.14% (last week), and 3.75% (last month), respectively.

Catalyst Pharmaceuticals’s Stock Yearly Top and Bottom Value

Catalyst Pharmaceuticals’s stock is valued at $5.84 at 01:22 EST, below its 52-week high of $6.22 and way higher than its 52-week low of $2.88.

Catalyst Pharmaceuticals’s Moving Average

Catalyst Pharmaceuticals’s value is higher than its 50-day moving average of $5.68 and way above its 200-day moving average of $4.77.

4. Perficient (PRFT)

13.1% sales growth and 10.89% return on equity

Perficient, Inc. provides digital consultancy services and solutions in the United States.

Perficient’s sales growth this year is anticipated to be 15.1% and 8.9% for next year.

Year-on-year quarterly revenue growth grew by 25.8%, now sitting on 673.71M for the twelve trailing months.

Volume

Today’s last reported volume for Perficient is 578687 which is 72.75% above its average volume of 334990.

Perficient’s sales growth for the next quarter is 13.1%. The company’s growth estimates for the ongoing quarter and the next is 35.1% and 17.9%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.89%.

Volatility

Perficient’s last day, last week, and last month’s current volatility was 0.23%, 2.50%, and 1.24%, respectively.

Perficient’s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 3.79% (day), 3.38% (last week), and 2.42% (last month), respectively.

Perficient’s Stock Yearly Top and Bottom Value

Perficient’s stock is valued at $94.29 at 01:22 EST, under its 52-week high of $96.87 and way higher than its 52-week low of $37.42.

Perficient’s Moving Average

Perficient’s worth is way above its 50-day moving average of $82.56 and way above its 200-day moving average of $67.48.

5. Western New England Bancorp (WNEB)

8.4% sales growth and 8.19% return on equity

Western New England Bancorp, Inc. operates as the holding company for Westfield Bank that provides commercial and retail banking products and services to individuals and businesses.

Western New England Bancorp’s sales growth this year is anticipated to be 9.3% and a negative 2.1% for next year.

Year-on-year quarterly revenue growth grew by 45.4%, now sitting on 78.46M for the twelve trailing months.

Volume

Today’s last reported volume for Western New England Bancorp is 73636 which is 48.39% below its average volume of 142667.

Western New England Bancorp’s sales growth for the next quarter is 8.4%. The company’s growth estimates for the current quarter and the next is 137.5% and 137.5%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.19%.

Volatility

Western New England Bancorp’s last day, last week, and last month’s current volatility was 2.71%, 1.09%, and 1.24%, respectively.

Western New England Bancorp’s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 4.79% (day), 2.50% (last week), and 2.22% (last month), respectively.

Western New England Bancorp’s Stock Yearly Top and Bottom Value

Western New England Bancorp’s stock is valued at $8.35 at 01:22 EST, below its 52-week high of $9.24 and way higher than its 52-week low of $4.92.

Western New England Bancorp’s Moving Average

Western New England Bancorp’s value is higher than its 50-day moving average of $8.15 and above its 200-day moving average of $8.00.

6. Civista Bancshares (CIVB)

5.7% sales growth and 10.97% return on equity

Civista Bancshares, Inc. operates as the financial holding company for Civista Bank that provides community banking services.

Civista Bancshares ‘s sales growth this year is expected to be 8.2% and a negative 2.9% for next year.

Year-on-year quarterly revenue growth grew by 29.2%, now sitting on 120.54M for the twelve trailing months.

Volume

Today’s last reported volume for Civista Bancshares is 37542 which is 28.62% below its average volume of 52593.

Civista Bancshares ‘s sales growth is a negative 0% for the present quarter and 5.7% for the next. The company’s growth estimates for the ongoing quarter and the next is 39% and 6.3%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.97%.

Volatility

Civista Bancshares ‘s last day, last week, and last month’s current volatility was 0.57%, 1.21%, and 1.67%, respectively.

Civista Bancshares ‘s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 1.18% (day), 2.57% (last week), and 2.70% (last month), respectively.

Civista Bancshares ‘s Stock Yearly Top and Bottom Value

Civista Bancshares ‘s stock is valued at $22.89 at 01:22 EST, under its 52-week high of $23.98 and way above its 52-week low of $11.25.

Civista Bancshares ‘s Moving Average

Civista Bancshares ‘s worth is higher than its 50-day moving average of $22.68 and higher than its 200-day moving average of $21.93.

LEAVE A REPLY

Please enter your comment!
Please enter your name here